Bingham Osborn & Scarborough’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-7,330
| Closed | -$551K | – | 96 |
|
|
2021
Q3 | $551K | Sell |
7,330
-1,229
| -14% | -$93.5K | 0.04% | 83 |
|
|
2021
Q2 | $666K | Buy |
8,559
+656
| +8% | +$48.8K | 0.05% | 71 |
|
|
2021
Q1 | $581K | Buy |
7,903
+879
| +13% | +$64.8K | 0.04% | 69 |
|
|
2020
Q4 | $548K | Sell |
7,024
-1,354
| -16% | -$104K | 0.04% | 66 |
|
|
2020
Q3 | $663K | Sell |
8,378
-528
| -6% | -$41.4K | 0.05% | 84 |
|
|
2020
Q2 | $657K | Buy |
8,906
+687
| +8% | +$51.7K | 0.05% | 81 |
|
|
2020
Q1 | $603K | Buy |
8,219
+1,414
| +21% | +$111K | 0.06% | 78 |
|
|
2019
Q4 | $591K | Buy |
6,805
+156
| +2% | +$12.8K | 0.05% | 88 |
|
|
2019
Q3 | $534K | Sell |
6,649
-515
| -7% | -$41.3K | 0.05% | 89 |
|
|
2019
Q2 | $573K | Buy |
7,164
+518
| +8% | +$39.7K | 0.05% | 85 |
|
|
2019
Q1 | $527K | Sell |
6,646
-609
| -8% | -$45.5K | 0.05% | 87 |
|
|
2018
Q4 | $529K | Buy |
7,255
+86
| +1% | +$6.07K | 0.05% | 82 |
|
|
2018
Q3 | $485K | Buy |
7,169
+1,511
| +27% | +$96.3K | 0.04% | 85 |
|
|
2018
Q2 | $328K | Buy |
5,658
+330
| +6% | +$18.6K | 0.03% | 102 |
|
|
2018
Q1 | $277K | Sell |
5,328
-659
| -11% | -$35.6K | 0.03% | 116 |
|
|
2017
Q4 | $321K | Sell |
5,987
-678
| -10% | -$37.6K | 0.03% | 101 |
|
|
2017
Q3 | $407K | Buy |
6,665
+157
| +2% | +$9.52K | 0.04% | 83 |
|
|
2017
Q2 | $398K | Buy |
6,508
+2
| +0% | +$122 | 0.04% | 79 |
|
|
2017
Q1 | $394K | Sell |
6,506
-828
| -11% | -$50.2K | 0.04% | 79 |
|
|
2016
Q4 | $412K | Buy |
7,334
+260
| +4% | +$15.2K | 0.04% | 77 |
|
|
2016
Q3 | $421K | Sell |
7,074
-144
| -2% | -$8.42K | 0.04% | 76 |
|
|
2016
Q2 | $397K | Sell |
7,218
-758
| -10% | -$40.3K | 0.05% | 81 |
|
|
2016
Q1 | $403K | Sell |
7,976
-1,023
| -11% | -$50.1K | 0.05% | 80 |
|
|
2015
Q4 | $454K | Sell |
8,999
-162
| -2% | -$8.17K | 0.06% | 70 |
|
|
2015
Q3 | $432K | Sell |
9,161
-111
| -1% | -$5.9K | 0.05% | 70 |
|
|
2015
Q2 | $504K | Buy |
9,272
+912
| +11% | +$51.1K | 0.06% | 68 |
|
|
2015
Q1 | $458K | Sell |
8,360
-2,136
| -20% | -$121K | 0.05% | 70 |
|
|
2014
Q4 | $569K | Sell |
10,496
-1,122
| -10% | -$62.5K | 0.07% | 65 |
|
|
2014
Q3 | $657K | Buy |
11,618
+4,503
| +63% | +$253K | 0.08% | 58 |
|
|
2014
Q2 | $393K | Buy |
7,115
+422
| +6% | +$23K | 0.05% | 69 |
|
|
2014
Q1 | $363K | Buy |
6,693
+264
| +4% | +$13.7K | 0.05% | 71 |
|
|
2013
Q4 | $307K | Buy |
6,429
+375
| +6% | +$17.1K | 0.04% | 75 |
|
|
2013
Q3 | $275K | Buy |
6,054
+1,052
| +21% | +$48K | 0.04% | 72 |
|
|
2013
Q2 | $222K | Buy |
+5,002
| New | +$223K | 0.04% | 80 |
|
Other funds holding MRK
Bingham Osborn & Scarborough's MRK Position: Q4 2021 in Review
Bingham Osborn & Scarborough sold out of Merck (MRK) in Q4 2021, closing a stake of 7,330 shares — an estimated $551K sold.
Bingham Osborn & Scarborough first reported a position in MRK in Q2 2013 and held it in 34 quarters. The position peaked at $666K in Q2 2021. 2,902 funds tracked by Wall St. Rank hold MRK as of Q4 2021.
- Bingham Osborn & Scarborough reported no remaining Merck position as of Q4 2021 after selling out during the quarter.
- Bingham Osborn & Scarborough sold 7,330 Merck shares in Q4 2021, an estimated $551K.
- Bingham Osborn & Scarborough first reported a position in Merck in Q2 2013 and held it in 34 quarters.
- Bingham Osborn & Scarborough's Merck position peaked at $666K in Q2 2021.
- 2,902 funds tracked by Wall St. Rank held Merck as of Q4 2021.
Based on Bingham Osborn & Scarborough's 13F filing for Q4 2021.